UPDATE 4-Medtronic's unchanged annual outlook clouds upbeat quarterly results

Abbott Laboratories -6.00%
Masimo Corporation -0.06%
Medtronic Plc -1.66%
DexCom, Inc. -0.50%
Danaher Corporation -2.20%

Abbott Laboratories

ABT

95.47

-6.00%

Masimo Corporation

MASI

178.29

-0.06%

Medtronic Plc

MDT

85.65

-1.66%

DexCom, Inc.

DXCM

61.23

-0.50%

Danaher Corporation

DHR

193.78

-2.20%

Shares drop 2.6% despite beating quarterly expectations

Company expects $300 million hit from tariffs in fiscal 2027

CEO says Danaher-Masimo deal will not change patient-monitoring market long term

Adds analyst comment in paragraph 2

By Padmanabhan Ananthan and Puyaan Singh

Feb 17 (Reuters) - Medtronic MDT.N surpassed Wall Street expectations for third-quarter profit and revenue on Tuesday, driven by strong demand for its heart devices, but its shares fell 2.6% after the company left its forecast for full-year adjusted profit unchanged.

Medtech firms have been riding a wave of increased adoption of newer technologies and a rebound in surgeries.

The forecast being maintained despite the quarterly beat implies fourth-quarter growth will slow, said Bernstein analyst Christian Moore.

Medtronic's finance chief, Thierry Pieton, told Reuters that although the company expects 6% revenue growth for the fourth quarter, extra tax costs will hurt some of the profit upside.

Medtronic expects an about $300 million hit from tariffs in fiscal 2027, up from around $185 million in fiscal 2026. It maintained its fiscal 2026 adjusted per share profit forecast at $5.62 to $5.66.

The company also faces fresh attention on its patient monitoring business after life sciences firm Danaher DHR.N struck a $9.9  billion deal to buy rival Masimo MASI.O on Tuesday.

Medtronic's acute monitoring segment houses its pulse-oximetry systems and operates a duopoly with Masimo.

Medtronic CEO Geoff Martha told Reuters that while Masimo's integration could create disruptions for Danaher, the deal is unlikely to change long-term competitive dynamics in the patient-monitoring market.

Sales in Medtronic's cardiovascular segment jumped 13.8% to $3.46 billion during the quarter, powered by strong demand for its pulsed field ablation (PFA) portfolio.

Although Medtronic's worldwide cardiac ablation heart device sales rose 80% in the quarter, including PFA, the growth missed buyside expectations, feeding a narrative that the PFA market has slowed in the last few months, said Moore.

Third-quarter revenue was $9.02 billion, beating analysts' average estimate of $8.91 billion, according to data compiled by LSEG.

Medtronic reported quarterly adjusted profit of $1.36 per share, above estimates of $1.33 per share.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.